2022
   Ljubljana, Slovenia

I-04 Aliénor Bergès Model informed drug development to accelerate clinical development in life cycle innovation Wednesday 09:45-11:15

I-06 Mattia Berton Repository of model parameters for physiologically based pharmacokinetic modelling in obese validated against triazolam and caffeine observed data Wednesday 09:45-11:15

I-07 Jantine Brussee Population PK modelling for the iminosugar lucerastat supports dose adaptation in patients with Fabry disease and moderate to severe renal impairment Wednesday 09:45-11:15

I-08 Laura Bukkems Relationship between factor VIII activity levels and bleeding for rFVIII-SingleChain in patients with severe hemophilia A Wednesday 09:45-11:15

I-09 Myriam Chartoire Investigation of the design of the capsaicin cough challenge test Wednesday 09:45-11:15

I-12 Vincent Croixmarie Dose selection and adaptation strategy in renal impaired patients for a phase 2 study with a Clinical Trial Simulation strategy Wednesday 09:45-11:15

I-13 Anna Dari Quantifying the Persistence of Immunogenicity After a Single Dose of Ad26.COV2.S in Humans Using a Mechanistic Modeling & Simulation Approach Wednesday 09:45-11:15

I-15 Alan Faraj Model-informed dose selection in phase-3 trials for prophylactic treatment with dalcinonacog alfa in adult and pediatric hemophilia B patients Wednesday 09:45-11:15

I-17 Thomas Frank Population pharmacokinetic/pharmacodynamic modeling to demonstrate comparability of exposure and activity of insulin aspart Sanofi Wednesday 09:45-11:15

I-18 Aline Fuchs The human FcRn transgenic mice Tg32 as a model for early assessment and prediction of human pharmacokinetics of monoclonal antibodies Wednesday 09:45-11:15

I-23 Chih-hsuan Hsin Hepatic impairment affects pharmacokinetics and pharmacodynamics of selatogrel, a novel subcutaneous P2Y12 receptor antagonist Wednesday 09:45-11:15

I-26 Angela Khodzhayev Esophageal Eosinophil Count and the Endoscopic Reference Score Remodeling Subscore Do Not Correlate in Placebo Treated Eosinophilic Esophagitis Patients: Phase 2 Proof-of-Concept and Phase 3 TREET Studies Wednesday 09:45-11:15

I-27 Jane Knöchel Accelerating clinical development of a novel PCSK9 antisense oligonucleotide using semi-mechanistic pharmacodynamic modelling Wednesday 09:45-11:15

I-29 Olivier Le Tilly Non-linear pharmacokinetics of eculizumab in atypical haemolytic uremic syndrome Wednesday 09:45-11:15

I-30 Feiyan Liu A system pharmacology Boolean network model for the TLR4-mediated host response in early sepsis Wednesday 09:45-11:15

I-31 Igor Locatelli A Bayesian mixed treatment comparison meta-analysis of pulmonary arterial hypertension therapies Wednesday 09:45-11:15

I-37 Joo Young Na Population pharmacokinetic analysis of omeprazole according to CYP2C19 polymorphism in elderly subjects Wednesday 09:45-11:15

I-41 Tiffany Pela Quality of Life and Symptom Burden Among Patients With Eosinophilic Esophagitis in a Real-World Setting Wednesday 09:45-11:15

I-42 Carlos Perez-Ruixo Population pharmacokinetic modelling of selexipag and its active metabolite after oral and intravenous administration in adult pulmonary arterial hypertension patients Wednesday 09:45-11:15

I-43 Christoph Pfaffendorf Population pharmacokinetic model of atovaquone in infants to adults Wednesday 09:45-11:15

I-45 Elodie Plan Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatment Wednesday 09:45-11:15

I-47 Mar Ribera I Armengol A perspective on the kinetics of the oral administration of Mirabegron to treat overactive bladder in spinal cord injury patients Wednesday 09:45-11:15

I-49 Karine Rodriguez-Fernandez External validation of a population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa Wednesday 09:45-11:15

I-50 Viktor Rognås An integrated semi-mechanistic model to predict the outcome of drug-target effects on the erythropoietic system Wednesday 09:45-11:15

I-52 Marina Savelieva Pharmacometrics and Integrated Evidence Generation: example of ligelizumab in Chronic Spontaneous Urticaria Wednesday 09:45-11:15

I-53 Daniel Seeler Towards a qualitative systems biology model to study the effect of blood flow responsive CCM and NO signaling on endothelial cell morphology Wednesday 09:45-11:15

I-54 Sejung Hwang Population pharmacokinetic analysis to investigate the effect of ethnicity for extrapolating data from Caucasians to Koreans in eslicarbazepine acetate therapy Wednesday 09:45-11:15

I-55 Alexander Solms Reduced FXI levels do not appear to increase bleeding risk in End-Stage Kidney Disease patients - results from an exploratory PK/PD and ER analysis of FXI-ASO Wednesday 09:45-11:15

I-56 Gilles Tiraboschi Population Pharmacokinetic and Pharmacodynamic Analyses of Olipudase alfa in Adult and Pediatric Patients with the rare Acid Sphingomyelinase Deficiency (Niemann-Pick) lysosomal storage disease Wednesday 09:45-11:15

I-57 Thi Quyen Tran Population pharmacokinetics of a truncated milk fat globule-EGF factor 8 (NP-011) for optimal dose prediction on liver fibrosis Wednesday 09:45-11:15

I-61 Paul van den Berg Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis Wednesday 09:45-11:15

I-64 Zhigang Wang Higher clearance of therapeutic antibodies is associated with worse endoscopic outcomes in patients with Crohn’s disease Wednesday 09:45-11:15